Biomarin Pharmaceutical Inc (BMRN): V Bryan Lawlis , director of Biomarin Pharmaceutical Inc sold 550 shares on Jun 20, 2016. The Insider selling transaction was reported by the company on Jun 21, 2016 to the Securities and Exchange Commission. The shares were sold at $82.77 per share for a total value of $45,523.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 21, 2016, Jean Jacques Bienaime (Chief Executive Officer) sold 41,666 shares at $80.55 per share price.On Jun 8, 2016, Daniel K Spiegelman (EVP, Chief Financial Officer) sold 1,649 shares at $89.14 per share price.Also, On May 31, 2016, Henry J Fuchs (EVP, Chief Medical Officer) sold 15,000 shares at $87.69 per share price.On May 19, 2016, Robert Baffi (EVP, Technical Operations) sold 5,000 shares at $87.05 per share price.
BioMarin Pharmaceutical: On Monday, Jun 20, 2016 heightened volatility was witnessed in BioMarin Pharmaceutical which led to swings in the share price. The shares opened for trading at $82.77 and hit $85.8 on the upside , eventually ending the session at $84.06, with a gain of 0.24% or 0.2 points. The heightened volatility saw the trading volume jump to 16,82,707 shares. The 52-week high of the share price is $151.75 and the company has a market cap of $13,645 M . The 52-week low of the share price is at $62.12.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).